# OnCo record cml-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/cml-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "cml-signalling" ;
  schema:name "Chronic myeloid leukaemia (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05220"@en, "Chronic myeloid leukemia"@en ;
  schema:description "KEGG's CML map is built around one fusion protein, BCR-ABL1, a kinase that never switches off and drives RAS, PI3K and STAT5 signalling. Because a single enzyme causes the disease, a single class of pill (imatinib and its successors) controls it in most patients."@en ;
  schema:url <https://onco.cc/pathways/cml-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05220>, <https://doi.org/10.1038/nrc1567> ;
  onco:related <https://onco.cc/pathways/bcr-abl1-signalling/> ;
  onco:cancers <https://onco.cc/cancers/cml/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/> ;
  onco:pathways <https://onco.cc/pathways/bcr-abl1-signalling/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ren-nat-rev-cancer/> .